Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan, Inc.    AGN

No quotes available
-- USD   0.00%
07/28 ALLERGAN : Teva receives US clearance for Actavis acquisition
07/28 ALLERGAN : Establishment Labs Expands Senior Leadership Team
07/28 ALLERGAN : Teva agrees to largest-ever drug divestiture in FTC pharm..
SummaryQuotesNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsSector news 

Allergan, Inc. : Allergan 3rd-Quarter Profit Edges Down; Weighs Options for Obesity Segment

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/30/2012 | 03:07pm CEST
   By Tess Stynes 
 

Allergan Inc.'s (AGN) third-quarter earnings edged down slightly as the maker of Botox and medical devices posted more one-time items, masking continued sales growth for top drug Botox.

Since the end of the quarter, Allergan said it is exploring strategic options for its obesity intervention business, including among other things, a potential sale of the unit.

For the year, the company raised the lower end of its guidance and now expects per-share earnings of $4.17 and $4.19 on product sales of $5.7 billion to $5.8 billion. Its prior view was for per-share profit of $4.15 to $4.19 and product sales of $5.65 billion to $5.8 billion.

For the current quarter, Allergan forecast per-share earnings of $1.18 to $1.20 on revenue of $1.47 billion to $1.55 billion. Analysts polled by Thomson Reuters most recently expected $1.20 and $1.51 billion, respectively.

Chief Executive David E.I. Pyott in August had commented that the company is watching carefully for signs of economic vulnerability, but doesn't see a threat to long-term goals. Allergan's cosmetic medical products seem to appeal to people with greater economic means and purchasing power, providing some shelter from economic turmoil, he said at the time.

Allergan reported a profit of $249.4 million, down from $249.8 million a year earlier. On a per-share basis, earnings were up at 82 cents from 81 cents amid fewer shares outstanding. Excluding acquisition and restructuring related charges and other items, earnings were up at $1.06 from 92 cents.

Revenue increased 6.4% to $1.41 billion. Product net sales were up 6.1% to $1.39 billion, and were up 9.4% excluding currency impacts.

The company in August forecast per-share earnings of $1.02 to $1.04 on revenue of $1.37 billion to $1.45 billion.

Gross margin rose to 86.7% from 85.8% amid the increased revenue.

Sales of Botox, which is used as a medical treatment and wrinkle-fighting cosmetic tool, rose 8.8% to $431.6 million.

Specialty pharmaceutical sales--which make up the bulk of Allergan's revenue-increased 8.1%, or roughly 11% excluding currency fluctuations.

Write to Tess Stynes at tess.stynes@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALLERGAN, INC.
07/28 ALLERGAN : Teva receives US clearance for Actavis acquisition
07/28 ALLERGAN : Establishment Labs Expands Senior Leadership Team
07/28 ALLERGAN : Teva agrees to largest-ever drug divestiture in FTC pharma merger cas..
07/28 TEVA PHARMACEUTICAL : Receives Clearance from the U.S. Federal Trade Commission ..
07/28 TEVA PHARMACEUTICAL : Agrees to Divest 79 Pharma Products to Settle Actavis Gene..
07/28DJU.S. HOT STOCKS : Hot Stocks to Watch
07/28 ALLERGAN : Teva's $$40.5 Billion deal expected to go through next week
07/27 ALLERGAN : Establishment Labs Expands Senior Leadership Team
07/27 Teva, Allergan win U.S. antitrust approval for generics deal
07/27 ALLERGAN : Teva expect to close $40.5B Allergan generic deal next week
More news
Sector news : Pharmaceuticals - NEC
07/28DJBRISTOL MYERS SQUIBB : -Myers Results Boosted by Cancer Drugs -- Update
07/28DJU.S. HOT STOCKS : Hot Stocks to Watch
07/28DJALEXION PHARMACEUTICALS : Cuts Profit Guidance
07/28DJBRISTOL MYERS SQUIBB : -Myers Results Boosted by Cancer Drugs
07/28DJBRISTOL MYERS SQUIBB : -Myers Results Boosted by Cancer Drugs
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 MANNKIND : A Head Pain Gain Or A Pocket-Book Drain?
2015 Tracking Dan Loeb's Third Point Portfolio - Q1 2015 Update
2015 Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2015 Update
2015 Time Warner Is A Buy - Cramer's Lightning Round (5/21/15)
2015 Tracking John Paulson's Paulson & Company Portfolio - Q1 2015 Update
Advertisement
Income Statement Evolution
More Financials
Managers
NameTitle
Ambrose Robert Douglas Bailey Chairman & President
Scott M. Whitcup Chief Scientific Officer & Executive VP-Research
Raymond H. Diradoorian Executive VP-Global Technical Operations
Maria Teresa Hilado Director
Joann Bradley Investor Relations Contact
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN, INC.13.00%0
JOHNSON & JOHNSON21.47%343 198
PFIZER INC.14.16%223 490
ROCHE HOLDING LTD.-9.99%216 972
NOVARTIS AG-5.30%216 918
MERCK & CO., INC.10.94%162 206
More Results